Financhill
Sell
41

STXS Quote, Financials, Valuation and Earnings

Last price:
$1.76
Seasonality move :
1.44%
Day range:
$1.70 - $1.80
52-week range:
$1.66 - $3.29
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
5.57x
P/B ratio:
24.89x
Volume:
489.8K
Avg. volume:
625.6K
1-year change:
-32.57%
Market cap:
$151.3M
Revenue:
$26.9M
EPS (TTM):
-$0.30

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
STXS
Stereotaxis
$6.9M -$0.07 -0.07% -20.83% $4.50
AXGN
Axogen
$48.3M $0.02 17.84% -76% $25.71
ELMD
Electromed
$15.8M -- 13.91% -- $37.00
IRIX
IRIDEX
$12.8M -$0.12 -2.72% -18.18% --
MYO
Myomo
$9.2M -$0.08 145.61% -24% $9.25
TMDX
TransMedics Group
$123.4M $0.24 27.41% -31.06% $102.86
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
STXS
Stereotaxis
$1.76 $4.50 $151.3M -- $0.00 0% 5.57x
AXGN
Axogen
$18.51 $25.71 $820.8M -- $0.00 0% 4.37x
ELMD
Electromed
$23.86 $37.00 $204.2M 31.81x $0.00 0% 3.58x
IRIX
IRIDEX
$0.99 -- $16.5M -- $0.00 0% 0.33x
MYO
Myomo
$4.81 $9.25 $165.4M -- $0.00 0% 5.58x
TMDX
TransMedics Group
$67.28 $102.86 $2.3B 66.61x $0.00 0% 5.37x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
STXS
Stereotaxis
-- 1.683 -- 0.74x
AXGN
Axogen
31.37% 1.667 6.53% 1.88x
ELMD
Electromed
-- 1.939 -- 4.68x
IRIX
IRIDEX
51.25% 1.717 9.47% 0.73x
MYO
Myomo
-- 2.090 -- 2.82x
TMDX
TransMedics Group
69.02% 2.597 24.3% 7.25x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
STXS
Stereotaxis
$3.2M -$7.6M -139.2% -139.2% -120.3% $1.3M
AXGN
Axogen
$37.6M $2M -6.89% -10.21% 4.56% $7.9M
ELMD
Electromed
$12.6M $2.5M 15.91% 15.91% 15.64% $2.9M
IRIX
IRIDEX
$4.3M -$1.9M -146.36% -157.91% -16.15% -$3.1M
MYO
Myomo
$8.6M -$245.3K -48.64% -48.64% -2.03% $2.5M
TMDX
TransMedics Group
$72M $8.6M 5.12% 19.17% 8.68% $6.1M

Stereotaxis vs. Competitors

  • Which has Higher Returns STXS or AXGN?

    Axogen has a net margin of -118.53% compared to Stereotaxis's net margin of 0.91%. Stereotaxis's return on equity of -139.2% beat Axogen's return on equity of -10.21%.

    Company Gross Margin Earnings Per Share Invested Capital
    STXS
    Stereotaxis
    50.73% -$0.09 $11.4M
    AXGN
    Axogen
    76.06% $0.01 $151.4M
  • What do Analysts Say About STXS or AXGN?

    Stereotaxis has a consensus price target of $4.50, signalling upside risk potential of 155.68%. On the other hand Axogen has an analysts' consensus of $25.71 which suggests that it could grow by 38.92%. Given that Stereotaxis has higher upside potential than Axogen, analysts believe Stereotaxis is more attractive than Axogen.

    Company Buy Ratings Hold Ratings Sell Ratings
    STXS
    Stereotaxis
    2 0 0
    AXGN
    Axogen
    5 0 0
  • Is STXS or AXGN More Risky?

    Stereotaxis has a beta of 1.602, which suggesting that the stock is 60.223% more volatile than S&P 500. In comparison Axogen has a beta of 0.995, suggesting its less volatile than the S&P 500 by 0.487%.

  • Which is a Better Dividend Stock STXS or AXGN?

    Stereotaxis has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Axogen offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Stereotaxis pays -- of its earnings as a dividend. Axogen pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios STXS or AXGN?

    Stereotaxis quarterly revenues are $6.3M, which are smaller than Axogen quarterly revenues of $49.4M. Stereotaxis's net income of -$7.5M is lower than Axogen's net income of $450K. Notably, Stereotaxis's price-to-earnings ratio is -- while Axogen's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Stereotaxis is 5.57x versus 4.37x for Axogen. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    STXS
    Stereotaxis
    5.57x -- $6.3M -$7.5M
    AXGN
    Axogen
    4.37x -- $49.4M $450K
  • Which has Higher Returns STXS or ELMD?

    Electromed has a net margin of -118.53% compared to Stereotaxis's net margin of 12.11%. Stereotaxis's return on equity of -139.2% beat Electromed's return on equity of 15.91%.

    Company Gross Margin Earnings Per Share Invested Capital
    STXS
    Stereotaxis
    50.73% -$0.09 $11.4M
    ELMD
    Electromed
    77.68% $0.22 $43.6M
  • What do Analysts Say About STXS or ELMD?

    Stereotaxis has a consensus price target of $4.50, signalling upside risk potential of 155.68%. On the other hand Electromed has an analysts' consensus of $37.00 which suggests that it could grow by 55.07%. Given that Stereotaxis has higher upside potential than Electromed, analysts believe Stereotaxis is more attractive than Electromed.

    Company Buy Ratings Hold Ratings Sell Ratings
    STXS
    Stereotaxis
    2 0 0
    ELMD
    Electromed
    2 0 0
  • Is STXS or ELMD More Risky?

    Stereotaxis has a beta of 1.602, which suggesting that the stock is 60.223% more volatile than S&P 500. In comparison Electromed has a beta of 0.594, suggesting its less volatile than the S&P 500 by 40.575%.

  • Which is a Better Dividend Stock STXS or ELMD?

    Stereotaxis has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Electromed offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Stereotaxis pays -- of its earnings as a dividend. Electromed pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios STXS or ELMD?

    Stereotaxis quarterly revenues are $6.3M, which are smaller than Electromed quarterly revenues of $16.3M. Stereotaxis's net income of -$7.5M is lower than Electromed's net income of $2M. Notably, Stereotaxis's price-to-earnings ratio is -- while Electromed's PE ratio is 31.81x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Stereotaxis is 5.57x versus 3.58x for Electromed. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    STXS
    Stereotaxis
    5.57x -- $6.3M -$7.5M
    ELMD
    Electromed
    3.58x 31.81x $16.3M $2M
  • Which has Higher Returns STXS or IRIX?

    IRIDEX has a net margin of -118.53% compared to Stereotaxis's net margin of -16.69%. Stereotaxis's return on equity of -139.2% beat IRIDEX's return on equity of -157.91%.

    Company Gross Margin Earnings Per Share Invested Capital
    STXS
    Stereotaxis
    50.73% -$0.09 $11.4M
    IRIX
    IRIDEX
    37.33% -$0.12 $5.4M
  • What do Analysts Say About STXS or IRIX?

    Stereotaxis has a consensus price target of $4.50, signalling upside risk potential of 155.68%. On the other hand IRIDEX has an analysts' consensus of -- which suggests that it could grow by 102.02%. Given that Stereotaxis has higher upside potential than IRIDEX, analysts believe Stereotaxis is more attractive than IRIDEX.

    Company Buy Ratings Hold Ratings Sell Ratings
    STXS
    Stereotaxis
    2 0 0
    IRIX
    IRIDEX
    0 0 0
  • Is STXS or IRIX More Risky?

    Stereotaxis has a beta of 1.602, which suggesting that the stock is 60.223% more volatile than S&P 500. In comparison IRIDEX has a beta of 0.737, suggesting its less volatile than the S&P 500 by 26.316%.

  • Which is a Better Dividend Stock STXS or IRIX?

    Stereotaxis has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. IRIDEX offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Stereotaxis pays -- of its earnings as a dividend. IRIDEX pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios STXS or IRIX?

    Stereotaxis quarterly revenues are $6.3M, which are smaller than IRIDEX quarterly revenues of $11.6M. Stereotaxis's net income of -$7.5M is lower than IRIDEX's net income of -$1.9M. Notably, Stereotaxis's price-to-earnings ratio is -- while IRIDEX's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Stereotaxis is 5.57x versus 0.33x for IRIDEX. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    STXS
    Stereotaxis
    5.57x -- $6.3M -$7.5M
    IRIX
    IRIDEX
    0.33x -- $11.6M -$1.9M
  • Which has Higher Returns STXS or MYO?

    Myomo has a net margin of -118.53% compared to Stereotaxis's net margin of -2.16%. Stereotaxis's return on equity of -139.2% beat Myomo's return on equity of -48.64%.

    Company Gross Margin Earnings Per Share Invested Capital
    STXS
    Stereotaxis
    50.73% -$0.09 $11.4M
    MYO
    Myomo
    71.39% -$0.01 $24.7M
  • What do Analysts Say About STXS or MYO?

    Stereotaxis has a consensus price target of $4.50, signalling upside risk potential of 155.68%. On the other hand Myomo has an analysts' consensus of $9.25 which suggests that it could grow by 92.31%. Given that Stereotaxis has higher upside potential than Myomo, analysts believe Stereotaxis is more attractive than Myomo.

    Company Buy Ratings Hold Ratings Sell Ratings
    STXS
    Stereotaxis
    2 0 0
    MYO
    Myomo
    3 0 0
  • Is STXS or MYO More Risky?

    Stereotaxis has a beta of 1.602, which suggesting that the stock is 60.223% more volatile than S&P 500. In comparison Myomo has a beta of 1.548, suggesting its more volatile than the S&P 500 by 54.752%.

  • Which is a Better Dividend Stock STXS or MYO?

    Stereotaxis has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Myomo offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Stereotaxis pays -- of its earnings as a dividend. Myomo pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios STXS or MYO?

    Stereotaxis quarterly revenues are $6.3M, which are smaller than Myomo quarterly revenues of $12.1M. Stereotaxis's net income of -$7.5M is lower than Myomo's net income of -$260.1K. Notably, Stereotaxis's price-to-earnings ratio is -- while Myomo's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Stereotaxis is 5.57x versus 5.58x for Myomo. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    STXS
    Stereotaxis
    5.57x -- $6.3M -$7.5M
    MYO
    Myomo
    5.58x -- $12.1M -$260.1K
  • Which has Higher Returns STXS or TMDX?

    TransMedics Group has a net margin of -118.53% compared to Stereotaxis's net margin of 5.64%. Stereotaxis's return on equity of -139.2% beat TransMedics Group's return on equity of 19.17%.

    Company Gross Margin Earnings Per Share Invested Capital
    STXS
    Stereotaxis
    50.73% -$0.09 $11.4M
    TMDX
    TransMedics Group
    59.21% $0.19 $737.9M
  • What do Analysts Say About STXS or TMDX?

    Stereotaxis has a consensus price target of $4.50, signalling upside risk potential of 155.68%. On the other hand TransMedics Group has an analysts' consensus of $102.86 which suggests that it could grow by 52.88%. Given that Stereotaxis has higher upside potential than TransMedics Group, analysts believe Stereotaxis is more attractive than TransMedics Group.

    Company Buy Ratings Hold Ratings Sell Ratings
    STXS
    Stereotaxis
    2 0 0
    TMDX
    TransMedics Group
    5 3 0
  • Is STXS or TMDX More Risky?

    Stereotaxis has a beta of 1.602, which suggesting that the stock is 60.223% more volatile than S&P 500. In comparison TransMedics Group has a beta of 2.138, suggesting its more volatile than the S&P 500 by 113.849%.

  • Which is a Better Dividend Stock STXS or TMDX?

    Stereotaxis has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. TransMedics Group offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Stereotaxis pays -- of its earnings as a dividend. TransMedics Group pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios STXS or TMDX?

    Stereotaxis quarterly revenues are $6.3M, which are smaller than TransMedics Group quarterly revenues of $121.6M. Stereotaxis's net income of -$7.5M is lower than TransMedics Group's net income of $6.9M. Notably, Stereotaxis's price-to-earnings ratio is -- while TransMedics Group's PE ratio is 66.61x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Stereotaxis is 5.57x versus 5.37x for TransMedics Group. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    STXS
    Stereotaxis
    5.57x -- $6.3M -$7.5M
    TMDX
    TransMedics Group
    5.37x 66.61x $121.6M $6.9M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

How High Could IBIT Go?
How High Could IBIT Go?

Recently, a surprising number of billionaire hedge fund managers have…

Is Raymond James Stock a Buy, Sell or Hold?
Is Raymond James Stock a Buy, Sell or Hold?

Raymond James Financial (NYSE:RJF) is one of America’s large financial…

Is JHX Stock a Buy Sell or Hold?
Is JHX Stock a Buy Sell or Hold?

James Hardie Industries (NYSE:JHX) is a manufacturer of outside building…

Stock Ideas

Buy
56
Is AAPL Stock a Buy?

Market Cap: $3.3T
P/E Ratio: 37x

Sell
46
Is MSFT Stock a Buy?

Market Cap: $2.8T
P/E Ratio: 32x

Sell
41
Is NVDA Stock a Buy?

Market Cap: $2.6T
P/E Ratio: 37x

Alerts

Buy
80
CORT alert for Apr 1

Corcept Therapeutics [CORT] is up 109.21% over the past day.

Sell
47
RGC alert for Apr 1

Regencell Bioscience Holdings [RGC] is up 26.1% over the past day.

Buy
74
COOP alert for Apr 1

Mr. Cooper Group [COOP] is up 14.4% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock